Centessa Pharmaceuticals gets FDA orphan drug status for SerpinPC in hemophilia B
Centessa Pharmaceuticals has secured orphan drug designation from the US Food and Drug Administration (FDA) for SerpinPC in hemophilia B treatment. According to the UK-based clinical-stage pharma company, SerpinPC is an inhibitor of activated protein C (APC). Centessa Pharmaceuticals is looking at Q4 2022 to kick-start registrational studies of SerpinPC. Based on the serpin family […]